Abstract Genetic variation in the leucine-rich repeat and Ig domain containing 1 gene (LINGO1) was recently associated with an increased risk of developing essential tremor (ET) and Parkinson disease (PD). Herein, we performed a comprehensive study of LINGO1 and its paralog LINGO2 in ET and PD by sequencing both genes in patients (ET, n=95; PD, n=96) and by examining haplotype-tagging single-nucleotide polymorphisms (tSNPs) in a multicenter Carles Vilariño-Güell and Christian Wider have contributed equally to this work.
Introduction
Essential tremor (ET) and Parkinson disease (PD) are prevalent age-related movement disorders affecting about 3-6% (ET) and 1-2% of individuals over the age of 65 years (PD) [1] [2] [3] [4] . While both ET and PD may cause significant motor impairment with tremor, they are regarded as distinct entities based on major differences at the clinical and pathological levels. ET patients display mostly symmetric action tremor which contrasts with asymmetric PD tremor that occurs at rest and is associated with bradykinesia, rigidity, and postural instability. Pathologically, some ET cases have Purkinje cell loss and Purkinje cell axonal dilations (torpedoes) in the cerebellum [5] . Some cases have α-synuclein immunopositive Lewy bodies (LB) in the brainstem [5] . Conversely, in PD there is severe neuronal loss in brainstem nuclei with abundant LB pathology [5, 6] . Despite these differences, clinical evidence indicates an overlap exists between ET and PD with a fourfold increased risk of PD in patients with ET, increased prevalence of ET in relatives of patients with PD and the presence of action tremor often preceding the onset of PD symptoms [7] . Furthermore, imaging studies found signs of dopaminergic deficiency in some ET patients and brainstem LB have been reported in ET cases [8] .
The leucine-rich repeat and Ig domain containing 1 gene (LINGO1) has recently been associated with an increased risk of developing ET and PD, providing the first evidence of a genetic link between the two diseases [9] . LINGO1 is a central nervous system-specific component of the Nogo-66 receptor (NgR1)/p75/LINGO1 signaling complex implicated in inhibition of oligodendrocyte differentiation, axonal myelination and regeneration, and neuronal survival [10] [11] [12] [13] [14] [15] [16] . Expression of LINGO1 is increased after neuronal damage or cell death and its inhibition promotes functional recovery and axonal sprouting after spinal cord injury [10, 14, 17] . The expression of LINGO1 is higher in the substantia nigra of patients with PD compared to age-matched controls and increases in ventral midbrain neurons in animal models of PD after neurotoxic lesions [10] . Furthermore, reduction of LINGO1 activity was shown to improve survival, growth, and function of dopaminergic neurons both in primary cell cultures and in vivo experimental models of parkinsonism in rodents [10, 18] . These data highlight the functional relevance of LINGO1 as a regulator of neuronal death, which is consistent with LINGO1 variability altering the risk for ET and PD [9, 19, 20] .
The leucine-rich repeat and Ig domain containing 2 gene (LINGO2) is a much less well characterized paralog of LINGO1. In contrast to the other LINGO1 paralogs (LINGO3 and LINGO4), LINGO2 expression is detectable in the mouse adult brain and appears to be restricted to neuronal tissue [21, 22] . We recently performed a genomewide association study in a PD patient-control series that identified single-nucleotide polymorphisms (SNPs) in SNCA and LRRK2 associated with increased disease risk (unpublished findings). Although none of the SNPs in LINGO2 were found to associate with PD after correction for multiple testing, nominal significant P values were observed. Given the high degree of homology between the LINGO1 and LINGO2 proteins (61%), and recently reported association studies, both LINGO1 and its paralog LINGO2 are reasonable candidate genes for ET and PD.
In the present study, we examine the role of LINGO1 and LINGO2 in ET and PD by sequencing both genes in a series of patients with ET (n=95) and PD (n=96), and by performing association studies in ET and PD patientcontrol series (combined n=2,522) using tagging SNPs (tSNPs) that capture >95% of the genetic variability of LINGO1 and LINGO2. We identified ten rare coding variants (nine novel) in LINGO1 and LINGO2; three of them did not segregate with disease within families. However, we found evidence suggesting LINGO1 and LINGO2 variation influences risk for and onset age of ET and PD, expanding the scope of genetic factors common to both diseases.
Methods

Study population
A total of 1,247 patients with ET, 633 patients with PD, and 642 control subjects of Caucasian origin from North America were included in this study (Mayo Table 1 . All patients were examined by a movement disorders neurologist and diagnosed with PD according to published criteria [23] or satisfied clinical criteria for definite or probable ET [24] . All sites obtained local ethics committee approval prior to subject enrollment. Individuals were informed of all aspects pertaining to their participation in the study and gave either written or proxy consent.
DNA sequencing of LINGO1 and LINGO2
Genomic DNA was extracted from peripheral blood lymphocytes using standard protocols. Primer pairs for LINGO1 and LINGO2 (available on request) were used to sequence all coding exons and exon-intron boundaries by polymerase chain reaction (PCR) in 95 randomly selected ET and 96 PD probands from the Mayo Clinic Jacksonville. PCR products were purified from unincorporated nucleotides using Agencourt bead technology (Beverly, MA, USA) with Biomek FX automation (Beckman Coulter, Fullerton, CA, USA). Sequence analysis was performed as previously described [25] . All novel variants were examined for disease segregation when possible in affected and unaffected family members by additional sequencing.
Genetic association analysis
The population frequency of six known coding variants with minor allele frequency (MAF) <10% and six novel LINGO1 and three LINGO2 variants was assessed in the case-control series. Selection of additional tSNPs was based on HapMap Phase II data using Haploview software [26] . The regions containing LINGO1 and LINGO2 exons from any reported transcript (±2.5 kb surrounding noncoding exons or ±10 kb for coding exons) were used for the selection of tSNPs. In total 16 tSNPs across LINGO1 and 21 across LINGO2 loci were selected to capture >95% of the polymorphic variation in these regions (MAF>5% and r 2 >0.8) in Caucasian population standards. Genotyping of tSNPs and of known and novel coding variants (MAF<10%), identified by sequencing, was performed on a Sequenom MassArray iPLEX platform (San Diego, CA, USA); all primer sequences are available on request. For each variant genotyping error was assessed by deviation from HardyWeinberg equilibrium expectation. All genotypes are given on the "+" strand.
Associations for PD and ET were evaluated using logistic regression models adjusted for age and gender; odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. Single SNP associations with age at disease onset were examined using linear regression models adjusted for gender; regression coefficients and 95% CIs were estimated. Due to the alternate association findings in previous reports, both dominant (major allele homozygote vs minor allele homozygote and heterozygote) and recessive (minor allele homozygote vs major allele homozygote and heterozygote) models were considered in all regression analyses. P values<0.05 were considered significant, and no adjustment for multiple testing was performed in this exploratory study.
Results
Sequencing analysis in 95 ET and 96 PD patients identified six novel coding variants in LINGO1 (Ser4Cys, Val107Met, Ala277Thr, Arg423Arg, Gly537Ala, and Asp610Asp) and three in LINGO2 (Asp135Asp, Pro217Pro, and Val565Val; Fig. 1 , Table 2 ). In addition five known polymorphisms were detected in LINGO1 (rs2271398, rs2271397, rs2271396, rs3743481, and rs61737308), four of which with a MAF>10%. Three novel variants in LINGO1 (Ser4Cys, Val107Met, and Gly537Ala) did not segregate with disease within families (Fig. 2) ; two of these variants, Ser4Cys and Gly537Ala, as well as Ala277Thr, Arg423Arg, and Asp610Asp in LINGO1 and Pro217Pro and Arg507His in LINGO2 were observed exclusively in cases and not in controls ( Table 2) .
Results of single SNP associations with ET and PD are presented in Table 3 . Whereas the original report and one replication study identified the minor allele of rs9652490 associated with an increased risk of ET [19, 20] The sample mean ± SD (range) is given for age and age at disease onset. Age at disease onset was only available in 396 ET and 423 PD cases previously identified association with ET and PD for the major allele [9] . The association study of LINGO1 tSNPs identified only the previously reported variant (rs9652490) being associated with both ET and PD under a recessive model (ET, OR=0.63, P=0.026; PD, OR=0.54, P=0.016).
The risk allele found to be overrepresented in the disease groups was the major allele (T; genotype frequencies are provided in Supplemental Table 1 ). This association is consistent with our previous report [9] but in disagreement with other studies [19, 20] . The reasons for this alternate association are unclear, but several theoretical hypothesis have been proposed [27] .
Additional associations with ET were identified for rs4886887, rs3144, rs8028808, and rs12905478 (Table 3) , spanning the entire LINGO1 gene (Fig. 1) . Similarly to the previously described association with rs9652490, the major alleles of rs8028808 and rs12905478 were overrepresented in cases resulting in protective ORs for the minor alleles (OR=0.49 and 0.36, respectively). However, for rs4883887 and rs3144, the associations were driven by the minor alleles (OR=1.83 and 1.48, respectively). No additional tSNPs in LINGO1 were found to be significantly associated with PD. The analysis of LINGO2 tSNPs in ET resulted in only one variant (rs1412229) being associated with disease Fig. 1 Schematic representation of the LINGO1 (top) and LINGO2 (bottom) genes indicating the exons (boxes) and the variants studied. Novel (above the genes) and known (below the genes) coding variants are given in bold. For LINGO1 exon arrangement was based on the two transcripts BC068558 and BC011057. The position of the start codon (ATG) was determined according to BC011057 rs/ss number Amino acid change Controls Essential tremor Parkinson disease Table 3 ). One variant in LINGO1 (rs907396) was associated with a 5-year younger mean age at ET onset (P=0.019). Association with the age of PD onset identified two variants conferring a later age at onset by approximately 5 years when the minor allele was present in homozygote form (rs4886887, P=0.047; rs3144, P=0.024; Supplemental Table 2 ). An earlier age at onset for ET by 4 to 5 years was also observed for two variants in LINGO2 (rs10812774 and rs7033345). In contrast, none of the variants in LINGO2 were significantly associated with age at onset of PD, however a trend toward an association (0.05≤P≤0.07) was observed for four variants (rs9644872, rs11793421, rs4879257, and rs6476092; Supplemental Table 2 ).
Discussion
Progress in the field of neurodegenerative disorders has highlighted the interplay of combined genetic factors in determining risk for complex traits. While variability in several genes may influence the risk for developing one disease, single genes often affect the risk for more than one trait. This diversity is best exemplified by variability in the tau (MAPT) and α-synuclein (SNCA) genes which alters risk of PD (MAPT and SNCA), progressive supranuclear palsy and corticobasal degeneration (MAPT), and multiple system atrophy (SNCA) [28] [29] [30] [31] . However, while a growing number of genes have been implicated in both sporadic and familial PD, genetic factors in ET have remained elusive [9, 32] . The LINGO1 SNP rs9652490 was recently shown to associate with ET, a finding that was replicated independently and extended to PD [9, 19, 20] . Taken together with the established role of LINGO1 in neuronal survival and the preliminary evidence implicating LINGO2 in PD, these data support LINGO1 and LINGO2 as candidate genes for ET and PD. In the present study, we examined this hypothesis by performing a comprehensive evaluation of both genes in a multicenter series of North American patients with ET and PD and in control subjects. The sequencing effort identified six novel coding mutations in LINGO1 and three in LINGO2. However, three of these variants did not display segregation with disease in three families including a multi-incident kindred with PD and ET. Identification of additional families will be required to examine segregation and assess pathogenicity of the other six novel variants. Although all nine novel variants were rare (MAF≤0.16%), six of them were found only in patients and not in control subjects, indicating a possible role in pathogenesis that warrants further studies. Interestingly, three of the six variants found only in patients were identified in both ET and in PD, which supports the notion that genetic factors may influence both diseases simultaneously.
The association study using tSNPs identified one variant in LINGO1 which alters the risk for both ET and PD (rs9652490), consistent with our previous report [9] . Odd ratios (OR), 95% confident intervals (CI), and P values were obtained from logistic regression models adjusted for age and gender MA, minor allele a Includes 428 control subjects, 353 ET, and 426 PD patients previously reported [9] Interestingly, there is a discrepancy between the results of our two studies and those of others in which the association with disease was driven by the minor allele of rs9652490 [19, 20] . Possible explanations include population-specific differences, although the largest series used in the replication part of the initial report was ethnically similar to our patient-control series (US Caucasians) [19] . Four additional variants in LINGO1 and one in LINGO2 influenced the risk of ET, and one SNP in LINGO2 altered the risk of PD. Furthermore, five variants in LINGO1 and LINGO2 had an effect on age at onset in ET (three variants) and PD (two variants). Despite the fact that these associations would not have withstood adjustment for the number of statistical tests performed and should therefore be considered exploratory, several lines of evidence are supportive including that: (1) LINGO1 is biologically plausible as a candidate gene for neurodegenerative disease; (2) this is the fourth study by three independent groups in Caucasian and Asian populations that consistently nominate variants in LINGO1 as a risk factor for developing ET; and (3) variants which display evidence of association with disease span the entire LINGO1 gene. Factors contributing to our results not withstanding correction for multiple testing may include diagnostic inaccuracy (known to occur in both ET and PD), or the use of genetically heterogeneous, admixed North American populations. Power is unlikely to have played a major role as our combined ET series is the largest studied so far and our PD population is adequately powered to detect associations within the range of expected magnitude. Assuming a disease prevalence of 1%, an allele frequency of 0.25, and an OR of 2, we have >99% power to detect a dominant and 84% for a recessive association in our ET case-control study and a >99% dominant and 72% recessive association in PD. A better molecular understanding of the pathogenesis for two prevalent movement disorders (ET and PD) will play a significant part in designing future therapeutic strategies aimed at prevention and cure. The results or our study support a role for LINGO1 and LINGO2 in determining risk for and onset age of ET and PD. Further replication studies on large and ethnically diverse populations are warranted to confirm these findings and to pave the way for the functional work that will unravel the pathogenic mechanisms involved.
